This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"I think it's really important, as we move to 2026 and beyond, we figure out ways to help pharmacies ease that burden and diversify their business." Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patientcare tips. Subscribe Now!
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patientcare tips? 2026 Edition. To read these stories and more, download the PDF of the Drug Topics May/June issue here. Sign up today for our free Drug Topics newsletter. REFERENCES 1. Yellow Book. Updated April 23, 2025.
Positive results have been announced from a phase 2a clinical trial evaluating the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients, Pelage Pharmaceuticals announced in a release. 1 The company said it plans to initiate phase 3 studies in 2026 to further evaluate the therapy.
Small Dispensers and the 6/12/2024 FDA Announcement Concerning DSCSA This week’s article on the recent DSCSA postponement comes from PRS Pharmacy Services. The exemption will last until November 27, 2026, for those small dispensers who qualify. We need more clarity here to see what the FDA is planning.
The FDA has accepted for review a New Drug Application (NDA) for doravirine/islatravir for adult patients with HIV-1 infection that is virologically suppressed on antiretroviral therapy, Merck announced in a release. 1 The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. References 1.
With rising drug costs, evolving health care regulations, and challenging reimbursement models, pharmacies must adopt strategic approaches to maintain financial health and continue providing patientcare.
The FDA approved clesrovimab-cfor (Enflonsia) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season, Merck announced in a release. READ MORE: Infectious Disease Resource Center Pharmacy practice is always changing. References 1.
All graduates should be ready for this, as our present Accreditation Council for Pharmacy Education Standards explicitly states: "Ensure that graduating students are ‘practice-ready’ and ‘team-ready,’ that is, prepared to directly contribute to patientcare working in collaboration with other health care providers."
The base year for the model was 2023, and the budget impact was projected from 2024 to 2026. 1 The investigators estimated a total of 63 million patients being 50 to 64 years of age, with about 24 million having chronic conditions that were eligible to receive a pneumococcal vaccine. REFERENCES 1.
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Telemedicine rose dramatically in many countries, providing a route to managing ongoing care which was a lifeline for many patients.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content